Medpace Holdings Stock Price and Value Analysis

Medpace Holdings (NasdaqGS:MEDP) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Medpace Holdings to reach your target.

Target type

MEDP Free Cash Flow Trend

Free Cash Flow trendline for MEDP
Free Cash Flow trendline for Medpace Holdings
CSV

Based on historical returns, we believe that Medpace Holdings can grow its free cash at a rate of about 36%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company has stable growth.
  • This company is making money at a great rate!
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the MEDP Numbers

MEDP Price
(Medpace Holdings stock price per share)
$610.54
[?] MEDP Fair Price
(based on intrinsic value)
$16.41
[?] MEDP Safety Price (based on a variable margin of safety) $9.85
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 67% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Diagnostics & Research stocks
[?] Free Cash Flow Jitter 22%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Medpace Holdings's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2023-09-21 Troendle August J. (CEO) Sell 61,655 $244.27
2023-09-21 Medpace Investors, LLC Sell 61,655 $244.27
2023-09-20 Troendle August J. (CEO) Sell 65,653 $255.48
2023-09-20 Medpace Investors, LLC Sell 65,653 $255.48

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,384,347 shares shorted. With 22,731,470 shares available for purchase and an average trading volume over the past 10 trading days of 178,810, it would take at least 7.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2015 1668397 79.4
2016 1668397 81.7
2017 1668397 86.8
2018 1668397 145
2019 1668397 189
2020 1668397 241
2021 1668397 242
2022 1668397 362
2023 1668397 403
2024 1668397 575
2025 1668397 679

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 10 fiscal years from 2015 to 2025 with positive net income, operating cash flow totaled $3,213 million against net income of $1,937 million, or 1.66 times. Net income was negative in 1 of the 11 years, and those years are left out of the ratio.

In 2025, operating cash flow was 1.58 times net income, compared with 3.60 times for the earliest three years (2015 to 2017).

In 2025, capital expenditures were $31.4 million, 4.4% of operating cash flow of $713 million, which leaves an estimated $682 million after capex. Across the 11 years with reported capex, it averaged 8.1% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 1.58, at least 0.25 under the 3.60 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2015 -8.7 85.9 6.5 n/a
2016 13.4 91.7 13.5 6.83
2017 39.1 97.4 11.7 2.49
2018 73.2 157 16 2.14
2019 100 202 17.9 2.01
2020 145 259 31.3 1.78
2021 182 263 28.3 1.45
2022 245 388 36.9 1.58
2023 283 433 36.6 1.53
2024 404 609 36.5 1.51
2025 451 713 31.4 1.58

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 7 fiscal years from 2017 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $2,589 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 7 of the 7 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $2,395 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $917 million, 135.1% of estimated free cash flow of $679 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2017 86.8 n/a 156 156 179.2%
2020 241 n/a 98.3 98.3 40.9%
2021 242 n/a 62.1 62.1 25.6%
2022 362 n/a 848 848 234.2%
2023 403 n/a 144 144 35.7%
2024 575 n/a 170 170 29.5%
2025 679 n/a 917 917 135.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $359 million in 2015 and $2,530 million in 2025, a compound annual growth rate of 21.6% over 10 years.

Revenue rose 20.0% from 2024 to 2025.

Our estimated free cash flow was $679 million in 2025, 26.8% of revenue. In 2015 the estimated margin was 22.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2015 359 79.4 22.1%
2016 422 81.7 19.4%
2017 436 86.8 19.9%
2018 705 145 20.5%
2019 861 189 21.9%
2020 926 241 26.0%
2021 1,142 242 21.2%
2022 1,460 362 24.8%
2023 1,886 403 21.4%
2024 2,109 575 27.3%
2025 2,530 679 26.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $497 million against total liabilities of $1,516 million, or 32.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 76.8% of total assets in 2025, compared with 58.0% in 2015, an increase of 18.8 percentage points.

Stockholders equity was $459 million in 2025, compared with $413 million in 2015, a rise of 11.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 504.4% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2015 984 14.9 571 413
2016 979 37.1 368 611
2017 951 26.5 441 509
2018 1,005 23.3 406 599
2019 1,143 132 417 726
2020 1,391 278 585 806
2021 1,660 461 707 953
2022 1,352 28.3 966 386
2023 1,657 245 1,098 559
2024 2,101 669 1,275 826
2025 1,975 497 1,516 459

Price Versus Our Estimated Value

Our fair value estimate for Medpace Holdings is $16.41, below its current price of $610.54.

Free cash flow was positive in all 11 fiscal years we have for Medpace Holdings under its current SEC filer.

Medpace Holdings's average free cash flow rose sharply, from $82.6 million in its earliest three years to $552 million in its latest three.

Year-to-year variability in free cash flow is fairly steady, measured at 22%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

We do not have a dividend yield for Medpace Holdings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 67% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Diagnostics & Research industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Diagnostics & Research industry, the ones closest in market capitalization to Medpace Holdings, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Medpace Holdings (MEDP) 17,078 33.9 - - 3621% above
Charles River Laboratories International (CRL) 15,061 341.7 - 2.1% 70% above
Incyte Corporation (INCY) 23,364 58.5 - 0.6% 166% above
Lantheus Holdings (LNTH) 6,677 25.4 - - 513% above
Quest Diagnostics Incorporated (DGX) 28,416 25.7 1.3% 3.0% 25% above
RadNet (RDNT) 5,491 - - 1.4% 42% below
National Research Corporation (NRC) 534 93.2 2.6% - 3712% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1668397.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: MEDP annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in MEDP

Does Medpace Holdings have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: MEDP

This example shows how we apply the Trendshare checklist to MEDP: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 610.54
    • Market cap: $17B
    • EPS: 18.01
  2. Step 2 — Valuation checks

    • P/E: 33.9
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.